Webinar: CLL Today – Understanding Your Treatment Choices

The 1st of September is World CLL Day, and we invite you to our next online educational webinar for patients and carers affected by chronic lymphocytic leukemia and small lymphocytic  leukemia (SLL).

In this webinar Professor Stephen Opat, Haematologist at Monash Health in Melbourne, will provide valuable insights into CLL and SLL, including current treatment approaches and developments, and how you can better understand your treatment options.

Event Details

Date: Tuesday 1st September
Time: 4:00pm to 5:00pm (NSW/VIC/QLD/ACT/TAS)
3:30pm to 4:30pm (SA/NT)
2:00pm to 3:00pm (WA)
Location: Online via Zoom – Link sent on registration
Cost: Free – Registration Required

Guest Presenter – Professor Stephen Opat

Professor Stephen Opat is an internationally renowned expert in chronic lymphocytic leukaemia and lymphoma and serves on/leads numerous international scientific advisory boards. He has a strong interest in medical education and is a highly sought after speaker having lectured widely throughout the Asia-Pacific with recent engagements in North America, Europe, South Africa and South America.

In addition to roles as faculty with the European Research Initiative on CLL (2024) and international workshop on CLL (2025). He is a global leader in defining the optimal care for lymphoid cancer survivors and has worked with patient groups including the US-based CLL Society and the UK-based CLL Advocates Network serving as a member of their Immunodeficiency Taskforce.

If you would like to submit any questions prior to the webinar, please email them through to nurse@lymphoma.org.au or call our Nurse Support Line on 1800 953 081

 

There is limited availability for this event, so secure your spot quickly.
This event has already taken place.
Details
Date: Tuesday 1st of September 2026
Time: 4:00pm AEST - 5:00pm AEST

Support and information

Contact Lymphoma Australia Today!

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.